iBioPharma, Inc. (OTCBB:IBPM) is focused on development and commercialization of novel plant-made products for the prevention and treatment of serious infectious diseases. To accelerate achievement of our objectives, we established a research & development relationship with a leading not-for-profit translational research institution, the Fraunhofer USA Center for Molecular Biotechnology (FhCMB). The success of this relationship has substantially reduced the risk of bringing important new medical products to market and has created a unique opportunity for investors.

We have achieved our initial goal of developing a platform technology for accelerated discovery and production of improved vaccines and therapeutics, and have applied our technology to create a pipeline of proprietary products, including vaccine and therapeutic candidates for seasonal and pandemic influenza, and other pathogens of public health significance.

This rapid technical success has attracted substantial additional funding to FhCMB from the Bill & Melinda Gates Foundation, the National Institutes of Health, the Defense Advanced Research Projects Agency (DARPA) and the U.S. Department of Defense.

In August 2008, iBioPharma, Inc. spun-off from Integrated BioPharma, Inc. (NasdaqGM:INBP). The Company was previously known as InB:Biotechnologies, Inc.

Integrated BioPharma (NasdaqGM:INBP) is a unique grouping of companies presently serving the varied needs of the health care industry. Through its core nutraceutical business, INBP creates, develops, manufactures and markets products worldwide. Through its subsidiary, AgroLabs, Inc., INBP distributes and markets healthful nutritional products under the following brands: Naturally Aloe, Naturally Noni, Naturally Pomegranate, Naturally Thai Mangosteen and most recently, Naturally Superberry Upgrade. Its subsidiary, InB:Manhattan Drug Company, manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers. INBP’s pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.integratedbiopharma.com.